Effect of a new cognition enhancer, alpha-glycerylphosphorylcholine, on scopolamine-induced amnesia and brain acetylcholine.
Level 5 - mechanism / opinion, no new human data
Animal and ex vivo laboratory study in rats
PubMed 1662399 · doi:10.1016/0091-3057(91)90040-9
What was done
Researchers evaluated the effect of intragastric/oral alpha-glycerylphosphorylcholine (alpha-GPC) on scopolamine-induced amnesia in rats using a passive avoidance paradigm. They also measured acetylcholine (ACh) concentrations across brain regions (hippocampus, cortex, and striatum) after scopolamine exposure and assessed potassium-stimulated ACh release from ex vivo rat hippocampal slices.
What was found
Alpha-GPC reversed scopolamine-induced memory deficits, with a peak effect at 600 mg/kg IG given 5 hours before training, showing duration of action up to 30 hours. Alpha-GPC partially counteracted scopolamine-induced reductions in ACh levels in the hippocampus and cortex, but not in the striatum. In ex vivo hippocampal slices, alpha-GPC increased potassium-stimulated ACh release. Specific numerical values, effect sizes, and statistical test outputs were not reported in the abstract.
Why it matters
This study provides foundational preclinical evidence that alpha-GPC acts as a bioavailable choline donor capable of enhancing central acetylcholine synthesis and reversing acute cholinergic receptor blockade deficits in rodent models.
Limits
The study is limited to an animal model and ex vivo tissue assays; human clinical relevance cannot be directly inferred. Total sample size (n) and exact quantitative metrics with confidence intervals or standard errors are omitted from the abstract. Scopolamine induces an acute pharmacological deficit that does not fully model chronic neurodegenerative diseases.
Cited by
- supports Alpha-GPC supplementation increases levels of acetylcholine in the nervous system.